WALTHAM, MA, September 15, 2017 –—A new study shows that the development of prostate cancer metastasis was associated with a five-fold increase in medical costs at the time of diagnosis, and substantially higher costs thereafter. Published in the May issue of Cancer, the scientific journal of the American Cancer Society, the study, titled “Impact of Subsequent Metastases on Costs and Medical Resource Use for Prostate Cancer Patients Initially Diagnosed with Localized Disease,” was conducted by BHE, the Carolina Urologic Research Center (CURC), and Janssen. Cancer also published an editorial by Drs. Daniel Frendl and Aria Olumi that discusses the value of this study’s data in the same issue of the journal.
The study, led by Drs. Tracy T. Li, PhD (Janssen), Neal D. Shore, MD, FACS (CURC), and Robert I. Griffiths, MS, ScD (BHE & Oxford University), utilized US national cancer registry data linked to Medicare insurance claims to evaluate a large population of men diagnosed with localized prostate cancer.
“In this study we were able to show that as the prostate cancer progresses, there are detrimental events not only clinically but also economically associated with metastatic disease.” stated Dr. Tracy Li, lead author of the study and Director of Health Economics and Market Access at Janssen.
Li et al found that almost half of the patients (48.6%) in the metastatic group required at least one inpatient admission around the time of diagnosis. In addition, utilization of outpatient resources also increased from 19% to 54% among patients in the metastatic group.
According to Dr. Neal Shore, Medical Director for the CURC, who has conducted over 250 clinical trials in genitourinary oncology, this study represents “the largest analysis of this population, and clearly demonstrates there is an unmet clinical need for intervention before metastatic disease diagnosis, as well as a significant economic impact for healthcare systems.”
Investigators at BHE, the CURC, and Janssen collaborated on the study, “Impact of Subsequent Metastases on Costs and Medical Resource Use for Prostate Cancer Patients Initially Diagnosed with Localized Disease.” Key investigators and their roles are listed below:
With over 20 years of impactful real world evidence (RWE) results, Boston Health Economics (BHE) continues to advance and innovate healthcare analytics research through technology-enabled, analytic solutions. BHE leverages cutting-edge data sources, expert methodological and clinical staff, and its proprietary technology solution, Instant Health Data, to quickly deliver actionable results to stakeholders across the healthcare industry. For more information, please follow us on LinkedIn and Twitter.
Carolina Urologic Research Center (CURC), is a separate and independent research arm of Grand Strand Urology, a division of Atlantic Urology Clinics in Myrtle Beach, SC. Under the direction of Dr. Neal Shore, CURC conducts phase I – IV drug, biotechnology and device trials focusing on urological diseases. CURC has been recognized both nationally & internationally as one of the most progressive, well-organized, and respected clinical research sites in the United States.
If you would like more information about this topic, please call Patricia Dickerson at 781-290-0808 or email firstname.lastname@example.org
View press release on PRWeb: http://bit.ly/BHECancerPRweb